Skip to main content
FDA Updates
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
Read More
FDA Updates
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
Read More
Editorial, Letters to the Editor, Infusion Issues, Adverse Events
JHOP Editorial Board Member, Readers, and Author Interact - Optimizing the Administration of Daratumumab
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Dr Soefje is Director, Pharmacy Cancer Care, Mayo Clinic, Rochester, MN.
Read More
Letters to the Editor, Editorial
JHOP Editorial Board Member, Readers, and Author Interact - Comment on Kye et al (April 2023), Authors’ Response
Read More
Original Research, Infusion Issues, Adverse Events, Monoclonal Antibodies
Incidence of Infusion-Related Reactions With Pertuzumab and Ado-Trastuzumab Emtansine: A Retrospective Study
Sara Moran Smith, PharmD, BCOP
Read More
Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Chemotherapy, Technology
Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist–Based Intravenous Chemotherapy Education and Follow-Up Program
Grant W. Lee, PharmD, BCOP; Joseen J. Chundamala, PharmD; Kerri L. Monahan, PharmD; Judy J. Cho, PharmD; Lydia J. Berry, RPh, PharmD; Christine G. Cambareri, PharmD, BCOP, CSP
Read More
Case Reports, PARP Inhibitors, Adverse Events, Oral Therapy, Ovarian Cancer
Successful Extended At-Home Olaparib Desensitization After a Hypersensitivity Reaction: A Case Report
Lily Y. Jia, PharmD, BCOP; Brendan Sendrowski, PharmD, BCOP, DPLA; Timothy Lax, MD; Meghan Shea, MD
Read More
Original Research, Antibiotics, Infections, Adverse Events, Oncology Pharmacy Programs/Protocols
Retrospective Evaluation of Initial Empiric Double Coverage with Tobramycin in Adult Patients with Febrile Neutropenia
Amber B. Clemmons, PharmD, BCOP, FHOPA; Rachel Shelley, PharmD; Vayou Chittavong, MS, PharmD; Huimin Hu, PhD; Xianyan Chen, PhD; Joshua Eudy, PharmD, BCIDP; Andrew Chao, MD; Daniel T. Anderson, PharmD, BCIDP
Read More
ASCO 2023 Highlights
Zanidatamab Plus Docetaxel Shows Promising Antitumor Activity in Advanced HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Prolonged Effectiveness With Tucatinib Plus Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer
Read More
Page 35 of 200
Results 341 - 350 of 1993